The combination of GPAT-IN-1 (glycerol-3-phosphate acyltransferase isoforms inhibitor) and erastin (a ferroptosis inducer and an SLC7A11 inhibitor) significantly enhanced the killing effect of cisplatin on SKOV3 DDP and A2780 DDP cells, which sheds new light on clinical strategies for overcoming platinum-resistant ovarian cancer. Here, SLC7A11 is linked to ovarian carcinoma.